Initiation and progression of liver fibrosis requires proliferation and activation of resting hepatic stellate cells (HSCs). Cyclin E1 (CcnE1) is the regulatory subunit of the cyclin-dependent kinase 2 (Cdk2) and controls cell cycle re-entry. We have recently shown that genetic inactivation of CcnE1 prevents activation, proliferation, and survival of HSCs and protects from liver fibrogenesis. The aim of the present study was to translate these findings into preclinical applications using an RNA interference (RNAi)-based approach. CcnE1-siRNA (small interfering RNA) efficiently inhibited CcnE1 gene expression in murine and human HSC cell lines and in primary HSCs, resulting in diminished proliferation and increased cell death. In C57BL/6 wild-type (WT) mice, delivery of stabilized siRNA using a liposome-based carrier targeted approximately 95% of HSCs, 70% of hepatocytes, and 40% of CD45 1 cells after single injection. Acute CCl 4 -mediated liver injury in WT mice induced endogenous CcnE1 expression and proliferation of surviving hepatocytes and nonparenchymal cells, including CD45
L
iver fibrosis develops as a consequence of chronic liver injury attributed to pathogenic stimuli, including chronic viral hepatitis or excessive alcohol consumption, leading to liver scarring by excessive accumulation of extracellular matrix (ECM) proteins. Initiation and progression of liver fibrosis induces cell proliferation of several hepatic cell types, including hepatocytes and hepatic stellate cells (HSCs). (1, 2) As a consequence of chronic liver damage and hepatocyte death, remnant hepatocytes leave their quiescent state and re-enter the cell cycle to restore original liver mass and function. Dying hepatocytes stimulate the conversion (i.e., activation) of resting, vitamin A-storing HSCs into proliferating, matrixAbbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; a-SMA, alpha smooth muscle actin; CcnE1, Cyclin E1; Cdk2, cyclin-dependent kinase 2; DAMP, danger-associated molecular pattern; DMEM, Dulbecco's modified Eagle's medium; ECM, extracellular matrix; FACS, fluorescence-activated cell sorting; HSC(s), hepatic stellate cell(s); huHSCs, human HSCs; IL, interleukin; NPC, non-parenchymal cell(s); MCP-1, monocyte chemoattractant protein 1; lCT-FMT, micro computed tomography/fluorescence molecular tomography; RANTES, regulated on activation, normal T-cell expressed and secreted; RB, retinoblastoma protein; RNAi, RNA interference; siRNA, small interfering RNA; TUNEL, TdTmediated dUTP-biotin nick end labeling; WT, wild type.
producing myofibroblasts, which is a prerequisite for fibrosis initiation.
The transition from cellular quiescence to proliferation is controlled by E-type cyclins (CcnE1, CcnE2) and their associated cyclin-dependent kinase 2 (Cdk2). (3) Surprisingly, knockout studies in mice revealed that single genetic inactivation of either CcnE1, CcnE2, or Cdk2 does not affect viability or development in mice most likely attributed to high functional redundancy with other cyclins and Cdks. (4) (5) (6) (7) In addition, CcnE1, CcnE2, and Cdk2 are dispensable for liver regeneration following partial hepatectomy (PH). However, combined inactivation of either CcnE1 and Cdk2 or CcnE1 and CcnE2 largely prevents compensatory hepatocyte proliferation in mice. (8, 9) We have recently identified a unique, nonredundant function of CcnE1 for activation, proliferation, and survival of HSCs in mice. (10) Accordingly, CcnE1
-/-knockout mice are protected from CCl 4 -induced liver fibrosis. (11) Therapeutic silencing of gene expression significantly progressed after discovering RNA interference (RNAi). (12) Short, double-stranded, small interfering RNAs (siRNAs) are 21-23 nucleotides in length with homology to a given target mRNA sequence. They are capable of degrading their target gene mRNA and suppressing its expression with high specificity. (13) Initially, siRNA was delivered in preclinical disease models by hydrodynamic tail vein injection in mice, resulting in efficient knockdown predominantly in the liver. (14) However, this delivery route cannot be translated into clinical applications in patients. The in vivo treatment with siRNA has been substantially improved by developing lipid-based carriers allowing repeated, well-tolerated, and highly efficient delivery of siRNA to liver cells. (15) In the present study, we aimed to translate our previous findings generated in CcnE1 -/-knockout mice into a preclinical antifibrotic therapy by siRNAmediated CcnE1 targeting. We show that therapeutic intervention with stabilized CcnE1-siRNA prevents liver fibrosis progression in mice and also mediates antifibrotic properties in primary human HSC.
Materials and Methods

MAINTENANCE OF MICE AND GENERAL ANIMAL EXPERIMENTATION
Animal experiments were carried out according to German legal requirements and animal protection laws and were approved by the authority for environment conservation and consumer protection of the state North Rhine-Westphalia (LANUV). Animals were housed in a temperature-controlled room with 12-hour light/dark cycles and free access to food and water.
For induction of liver fibrosis and in vivo siRNA delivery, we used male C57BL/6 wild-type (WT) mice at the age of 6-8 weeks. Mice with hepatocyte-specific deletion of CcnE1 (CcnE1 Dhepa ) have been described. (8) Acute liver injury and liver fibrosis were induced with CCl 4 . (11) Briefly, mice were injected with CCl 4 (0.6 mL/kg of body weight, intraperitoneally; Merck, Darmstadt, Germany) diluted in corn oil. Acute liver injury was induced by a single injection of CCl 4 and animals were euthanized 12-72 hours posttreatment. In the chronic fibrosis model, animals were injected with CCl 4 three times a week (every 48 hours) for 4-6 weeks and euthanized 48 hours after the last injection.
CcnE1-specific stabilized siRNA (Ambion in vivo predesigned) was obtained from Life Technologies (now: ThermoScientific, Waltham, MA). Three different siRNA molecules referred to as CcnE1-si #1, #2, and #3 were used. CcnE1 target sequences are listed in Supporting Table S1 . As control, a commercial scrambled (scr) siRNA (AMBIV NEGCTL1, order# 4457289; ThermoScientific) was used.
In vivo siRNA delivery was performed by weekly injection (24 hours after the second CCl 4 injection) of
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scrambled or CcnE1-siRNA (0.7 mg/kg, intravenously) in 200 lL of Invivofectamin2.0 (ThermoFisher Scientific, Waltham, MA), according to the manufacturer's instructions.
IN VITRO siRNA TRANSFECTION
Transfection of HSC with CcnE1-siRNA was performed in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum using lipofectamin3000 (ThermoFisher Scientific) and 25 pmol of siRNA in six-well plates, according to the manufacturer's instructions. Murine GRX and bonemarrow-derived cells were transfected with CcnE1-si #2; human LX2 cells were transfected with CcnE1-si #3. Medium was changed 24 hours posttransfection, and cells were subsequently cultured in DMEM.
STATISTICAL ANALYSIS
Data are expressed as mean 6 standard error (SEM) of the mean. Statistical significance was determined by two-way analysis of variance, followed by a Student t test.
Results
siRNA-MEDIATED INHIBITION OF CcnE1 ATTENUATES PROLIFERATION AND SURVIVAL IN MURINE AND HUMAN HSCs
The murine HSC line, GRX, is transfectable with siRNA, revealing a >90% transfection efficiency (Supporting Fig. S1A ). Transfection of a specific siRNA directed against the murine CcnE1 (CcnE1-si) efficiently reduced its expression on the gene and protein level (Supporting Fig. S1B,C) . The retinoblastoma protein (Rb) is a main substrate of the CcnE1/ Cdk2 kinase complex. (16) Rb phosphorylation was substantially diminished in CcnE1-si-transfected GRX cells (Supporting Fig. S1C ). We observed reduced cell density and significantly reduced proliferation in CcnE1-si-transfected cells compared to controls (Supporting Fig. S1D ,E) and a significant increase in the subG1 fraction of apoptotic cells (Supporting Fig.  S1F ). To exclude that the observed effects of CcnE1-siRNA are restricted to immortalized cell lines, we confirmed our approach in primary murine HSCs, showing substantially reduced HSC proliferation after efficient (approximately 80%) RNAi-mediated knockdown of CcnE1 (Supporting Fig. S2A-F) . Altogether, these in vitro data demonstrate the feasibility of RNAi-mediated CcnE1 inhibition in HSCs.
In order to translate our findings from mice into patients with activated HSCs, we reproduced our results in the human HSC line, LX2, and in primary human HSCs (huHSCs). Transfection efficiency for siRNA was >90% in LX2 cells and approximately 60% in huHSCs (Fig. 1A) , resulting in strongly reduced CcnE1 gene expression, protein levels, and substantially impaired phosphorylation of RB (Fig.  1B) . Consistent with our results in murine cells, CcnE1-siRNA triggered pronounced reduction of proliferation in LX2 cells (Fig. 1C ) and in huHSCs (Fig. 1D) . In addition, inhibition of CcnE1 was proapoptotic in both human cell types (Fig. 1E) . In summary, these results suggested that siRNA-mediated CcnE1 inhibition acts antifibrotic by blocking proliferation and survival of HSCs.
SYSTEMIC RNAi TREATMENT IN MICE PREDOMINANTLY TARGETS THE LIVER, INCLUDING ALL MAJOR HEPATIC CELL POPULATIONS
We next determined the uptake, distribution, and persistence of siRNA in mice after appropriate delivery. We applied Alexa 647-labeled scrambled siRNA to C57BL/ 6 WT mice using a lipid-based transfection reagent (Invivofectamine2.0) and performed noninvasive in vivo hybrid micro computed tomography/fluorescence molecular tomography (lCT-FMT) optical imaging over time (0.25-24.0 hours). The longitudinal imaging of the biodistribution showed immediate siRNA uptake in the liver ( Fig. 2A) , without significant accumulation in other organs (Fig. 2B) . Ex vivo fluorescence-reflectance imaging of explanted organs 24 hours postinjection confirmed predominant siRNA accumulation in liver and residual persistence in spleen (Fig. 2C) .
For tracking of siRNA on the cellular level, we isolated the main hepatic cell populations from recipient mice 1 day posttransfection and analyzed the percentage of Alexa 647-positive cells by fluorescenceactivated cell sorting (FACS). This measurement revealed that >90% of HSCs and 70% of hepatocytes were transduced with siRNA. Importantly, 40% of hepatic CD45
1 leukocytes and 90% of CD31 1 endothelial cells were also transfected (Fig. 2D) . In more detail, Alexa 647-labeled siRNA was detectable in the majority of hepatic CD11b 1 macrophages (85%) as well as in 25% of the Ly6G 1 neutrophils and CD19 1 B cells. Importantly, CD3 1 T cells were barely transfectable in our setting. For circulating blood leukocytes, we found a similar score of transfected cells, although at a strongly reduced relative frequency (Supporting Fig. S3A ,B).
INHIBITION OF HEPATIC CcnE1 THROUGH RNAi IN ACUTE CCl 4 -MEDIATED LIVER INJURY IS HEPATOPROTECTIVE AND ASSOCIATED WITH DELAYED PROLIFERATION OF HEPATOCYTES
Our pilot experiments demonstrated that RNAi is suitable to target HSC in vivo. We thus tested three different CcnE1-specific siRNA molecules in the CCl 4 -model of acute liver injury. To this end, we injected four cohorts of WT mice with either one of three distinct CcnE1-siRNAs (#1, #2, and #3) or scrambled (scr-si) control. Twenty-four hours after siRNA delivery, mice were challenged with CCl 4 and euthanized 48 hours later. CCl 4 treatment resulted in typical centrolobular necrosis (Fig. 3A) .
CcnE1 gene expression is usually low or absent in the resting liver, but induced 48 hours post-CCl 4 treatment. (10) Accordingly, CCl 4 treatment resulted in a 4-to 6-fold induction of CcnE1 mRNA expression in mice with or without scrambled siRNA (Fig. 3B) . However, two of three CcnE1-siRNAs (#2, #3) were capable of reverting CcnE1 induction to baseline levels, whereas the third molecule (#1) revealed only minor effects.
Analysis of CcnE1 and pRB protein expression confirmed this finding and clearly demonstrated that #2 was the most efficient siRNA capable to drop CcnE1 protein and CcnE1 kinase activity to almost baseline level of nonstimulated mice (Fig. 3B) . Interestingly, efficient CcnE1 inhibition correlated with remarkable reduction of alanine aminotransferase (ALT) activity, pointing to reduced overall liver injury (Fig. 3C) .
We next investigated cell-cycle activity in CCl 4 / CcnE1-siRNA-treated livers. In mice transfected with scrambled siRNA, CCl 4 treatment induced massive proliferation of hepatocytes as expected (Fig. 3D,E) . In contrast, efficient knockdown of CcnE1 by siRNA #2 or #3 significantly reduced hepatic cell proliferation, whereas the less specific siRNA #1 had no effect.
Altogether, we identified two CcnE1-siRNAs with strong inhibitory potential and hepatoprotective effects in vivo. All subsequent experiments were performed with siRNA #2 at a concentration of 0.5 nmol/g mouse showing optimal CcnE1 inhibition in vivo (Fig. 3F) .
HEPATOPROTECTION THROUGH RNAi-MEDIATED CcnE1 INHIBITION IS ASSOCIATED WITH DELAYED PROLIFERATION OF HEPATOCYTES AND ENHANCED HYPERTROPHY
The observed hepatoprotective effect of CcnE1-siRNA in acute CCl 4 -mediated liver injury was unexpected and thus investigated in more detail. Shortly after CCl 4 exposure (i.e., 12 hours postinjection) mice treated with scr-siRNA or CcnE1-siRNA had identical levels of liver injury determined by histological analyses and measurement of ALT and aspartate aminotransferase (AST) activities (Supporting Fig. S4A,  B) . In good agreement, CcnE1-siRNA did not affect the early regulation of the CCl 4 -metabolizing enzyme, cytochrome P450 2E1 (Supporting Fig. S4C ). Under these conditions, basal proliferation in leukocytes or hepatocytes was barely detectable and identical in all groups, suggesting that regeneration was not yet induced by CCl 4 (Supporting Fig. S4D ). The relative frequency of CD11b 1 myeloid cells and monocytes was also identical in scr-siRNA-and CcnE1-siRNAtreated livers (Supporting Fig. S4E ). As expected, we did also not find any significant changes in alpha smooth muscle actin (a-SMA) or collagen1a1 expression at this early stage (Supporting Fig. S4F ). Altogether, these controls demonstrate that scr-siRNAand CcnE1-siRNA-treated livers had identical levels of initial liver injury and comparable immune responses shortly post-CCl 4 exposure.
We extended the analysis of hepatic injury and proliferation to 72 hours post-CCl 4 treatment. Hepatoprotective effects in CcnE1-si-treated mice were restricted to 24-48 hours post-CCl 4 as evidenced by significantly reduced ALT activity (Fig. 4A) , whereas CcnE1 remained down-regulated 72 hours post-CCl 4 treatment (Fig. 4B) . Surprisingly, hepatic liver lesions were almost completely repaired in the CcnE1-si RNA treatment group, but not in controls (Fig. 4C) . Proliferation of CcnE1-si-treated hepatocytes was reduced 48 hours post-CCl 4 treatment (see Fig. FIG. 3 . Inhibition of hepatic CcnE1 through RNAi in acute CCl 4 -mediated liver injury is hepatoprotective and associated with delayed proliferation of hepatocytes. C57BL/6 mice were injected with three different siRNA molecules directed against CcnE1 (si #1, si #2, and si #3) or scrambled siRNA (scr-si) 24 In vivo dosage finding using increasing concentrations of CcnE1-si #2. Knockdown efficiency was verified by CcnE1 mRNA expression analysis. *P < 0.05; **P < 0.01; ***P < 0.001. Abbreviations: GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HPF, high-power field; n.s., not significant. 0 ,6-diamidino-2-phenylindole; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; H&E, hematoxylin and eosin; HNF4a, hepatocyte nuclear factor 4 alpha; HPF, highpower field; n.s., not significant. 3D,E), but significantly elevated after 72 hours compared to controls. Hence, the cell cycle in these cells was not arrested, but rather delayed. In contrast, the proliferation block in nonparenchymal cells (NPCs) after CcnE1-si treatment was persistent (Fig. 4C) .
Liver regeneration and wound healing can occur without cell division by cellular hypertrophy. (17) We thus determined the amount and size of hepatocytes as described recently. (8) CcnE1-siRNA per se did not affect the size or number of hepatocytes under basal conditions. However, we observed significantly enlarged size, but reduced numbers of hepatocytes, in CcnE1-si/CCl 4 co-treated livers (Fig. 4D) , pointing to liver regeneration by hypertrophic hepatocyte growth in absence of CcnE1. In good agreement, the liver mass index in the CcnE1-siRNA treatment group was significantly reduced 72 hours post-CCl 4 (Fig.  4E) . We further investigated this hypothesis in mice with hepatocyte-specific deletion of CcnE1 (CcnE1 Dhepa ). We did not observe hepatoprotection in CcnE1 Dhepa mice after acute or chronic CCl 4 treatment (Supporting Fig. S5A ). However, we found a tendency toward slightly reduced fiber formation in CcnE1 Dhepa mice after chronic CCl 4 challenge (Supporting Fig. S5B ) associated with reduced hepatocyte proliferation, whereas proliferation of inflammatory cells was unchanged (Supporting Fig. S5C,D) .
HEPATOPROTECTION THROUGH RNAi-MEDIATED CcnE1 INHIBITION IS ASSOCIATED WITH REDUCED INFILTRATION AND PROLIFERATION OF LEUKOCYTES
The previous data (compare Fig. 4C ) revealed a pronounced reduction of proliferating NPCs after CcnE1-si/CCl 4 co-treatment. Single CCl 4 treatment resulted in an increase of hepatic CD45 1 leukocytes and also in induction of leukocyte proliferation in the liver. In turn, CcnE1-siRNA reduced overall infiltration, but also proliferation of liver-resident CD45 1 cells (Fig. 5A ). Detailed analysis revealed that CcnE1-siRNA prevented especially the increase and proliferation of CD11b 1 myeloid cells (Fig. 5B) , whereas the persistence and proliferation of CD3 T cells and CD31 1 endothelial cells was not affected (Fig. 5C and Supporting Fig. S7A ). In good agreement, CcnE1-siRNA treatment significantly reduced expression of the proinflammatory and profibrotic chemokine, monocyte chemoattractant protein 1 (MCP-1), whereas expression levels of interleukin (IL)-10 (protective) or regulated on activation, normal T-cell expressed and secreted (RANTES; profibrotic) were not affected (Fig. 5D) . In summary, CcnE1-siRNA delivery prevented proliferation of CD45 
siRNA-MEDIATED INHIBITION OF CcnE1 PREVENTS INITIATION OF LIVER FIBROSIS
We tested, in a prevention model, whether siRNAmediated inhibition of CcnE1 attenuates fibrosis initiation. Initially, we treated C57BL/6 mice with CCl 4 three times per week for 4 weeks. In addition, mice received CcnE1-siRNA or scrambled siRNA 3 days before the first CCl 4 injection and once a week thereafter (Fig. 6A) . Continuous CcnE1-siRNA treatment resulted in substantial reduction of CcnE1 expression and prevented phosphorylation of the downstream target, RB (Fig. 6B) . Of note, total chronic liver injury (AST, ALT) and liver function (bilirubin) were not affected by CcnE1-siRNA (Supporting Fig. S6 ). Inhibition of CcnE1 revealed significant antifibrotic effects demonstrated by lack of Sirius Red-positive bridging fibrosis, as well as reduced overall collagen and hydroxyproline content. Semiquantitative scoring according to Ishak (18) indicated a tendency toward reduced fibrosis, which was, however, not significant after short-term challenge (Fig. 6C) . Therefore, we extended the profibrotic CCl 4 treatment to 6 weeks, resulting in pronounced fibrosis (Ishak fibrosis score, >4; Fig. 6D ). CcnE1-siRNA treatment significantly reduced liver fibrosis, evidenced by fibrosis scoring and decreased key fibrosis markers hydroxyproline, Collagen1a1, and a-SMA expression. As expected, CcnE1 gene expression was still reduced to baseline levels associated with coinhibition of the orthologue, CcnE2 (Fig. 6D ).
CcnE1 INHIBITION LEADS TO HSC APOPTOSIS AND REDUCED HEPATIC INFLAMMATION
We systematically investigated the effects of CcnE1-siRNA in HSCs, hepatocytes, and leukocytes after chronic CCl 4 challenge. In situ fluorescence staining revealed TdT-mediated dUTP-biotin nick end labeling (TUNEL)/Desmin double-positive cells within fibrotic areas in CcnE1-siRNA-treated livers, (Ishak) , and quantified by measurement of hepatic hydroxyproline content, and gene expression of collagen1a1 and a-SMA. Gene expression levels of CcnE1 and CcnE2 were determined by qPCR. *P < 0.05; ***P < 0.001. Abbreviations: GAPDH, glyceraldehyde 3-phosphate dehydrogenase; n.s.: not significant; pRB, Rb phosphorylation; w, weeks.
indicating that inhibition of CcnE1 triggers death of activated HSC (Fig. 7A ). In agreement with our data from acute liver injury and CcnE1 Dhepa mice (Fig. 4  and Supporting Fig. S5 ), we observed diminished proliferation of hepatocytes and hepatic NPCs attributed to CcnE1 inhibition (Fig. 7B) . In addition, CcnE1-siRNA treatment significantly reduced the total number and proliferation of hepatic CD45
1 leukocytes and especially of CD11b 1 myeloid cells (Fig. 7C,D) . The amount of proliferating CD3
1 T cells or CD31 1 endothelial cells was not modulated by CcnE1-siRNA (Supporting Fig. S7B,C) . The antifibrotic effect of CcnE1-siRNA also correlated with significant induction of IL-10 and down-regulation of RANTES (Supporting Fig. S7D ).
We confirmed the antiproliferative effect of CcnE1-siRNA on CD11b 1 cells in vitro. In agreement with in vivo findings, reduction of CcnE1 in bonemarrow-derived CD11b 1 cells leads to reduced proliferation (Fig. 7E ), but not to enhanced apoptosis (Supporting Fig. S8 ).
THERAPEUTIC INTERVENTION WITH CcnE1-siRNA PREVENTS FIBROSIS PROGRESSION
Finally, we tested the therapeutic benefits of CcnE1-siRNA after onset of liver fibrosis. Therefore, we initiated early fibrosis in mice with CCl 4 and started CcnE1-siRNA treatment thereafter (Fig. 8A) . CCl 4 treatment for 3 weeks resulted in moderate fibrosis (Ishak score, 3), which further progressed to advanced fibrosis after 6 weeks (Fig. 8B,C) . However, therapeutic intervention with CcnE1-siRNA 3 weeks post-CCl 4 treatment largely prevented further fibrosis progression despite ongoing continuous liver damage, as evidenced by semiquantitative scoring, hepatic hydroxyproline content, collagen measurements, and a-SMA expression analysis (Fig. 8C) . Of note, particularly strong down-regulation of collagen and a-SMA gene expression points to a direct inhibitory effect of CcnE1-siRNA on HSC activation. Interventional CcnE1-siRNA application was sufficient to drop CcnE1 gene expression to baseline levels, whereas CcnE2 expression was not significantly reduced (Fig. 8D) .
Discussion
Liver fibrosis is a continuous wound-healing response. In this process chronic liver injury triggers the transition of quiescent hepatocytes and HSCs into the cell cycle. The exit from quiescence is controlled by E-type cyclins (CcnE1, CcnE2). Therefore, we hypothesize that CcnE1-dependent activation of the cell cycle in hepatic cell populations is a prerequisite for liver fibrogenesis.
Previous studies suggested that CcnE1 might be an attractive target for antifibrotic therapy. First of all, CcnE1 has a unique, essential function in liver fibrogenesis for activation, proliferation, and survival of HSCs, whereas its orthologue, CcnE2, is neither involved in human nor murine liver fibrosis. (10) Besides that, CcnE1 is absolutely dispensable for normal organ homeostasis under healthy conditions in virtually all tissues (5) and is not necessary for liver regeneration, at least post-PH. (9) Thus, directed targeting of CcnE1 could specifically block fibrosis-related proliferation without mediating systemic side effects in other healthy cell populations. Small-molecule inhibitors specifically directed against CcnE1 are currently not available. At present, the only possibility to pharmacologically inhibit the CcnE1/Cdk2 kinase complex is by Cdk inhibitors, such as Roscovitine, (19) involving broad off-target effects (20) and the risk of seriously impaired liver regeneration.
In the present study, we aimed to translate our previous findings from genetic CcnE1 knockout mouse models (10) into a preclinical antifibrotic therapy using RNAi. Given that the liver is a particularly attractive organ for RNAi delivery, (13) this approach appeared most promising and allowed specific CcnE1 targeting.
In proof-of-concept studies, we demonstrated that CcnE1-siRNA has antiproliferative and proapoptotic effects in established murine and human HSC lines and thus acts basically antifibrotic. Importantly, CcnE1-siRNA revealed the same beneficial properties in primary human HSCs, which is a prerequisite for successful translation of our strategy to patients with liver fibrosis. Of note, CcnE1-si delivery co-inhibited expression of its orthologue, CcnE2. This closely corresponds with previous genetic data showing that hepatic CcnE2 expression is reduced in CcnE1 -/-mice, pointing to a regulatory feedback loop from CcnE1 to CcnE2. (9) We thus cannot exclude that indirect co-inhibition of CcnE2 expression further enhances the antifibrotic effects of CcnE1-siRNA.
Our study demonstrates that systemic delivery of stabilized CcnE1-siRNA in vivo only once a week is sufficient to inhibit CcnE1 induction in acute liver injury and chronic liver injury and to prevent initiation of liver fibrosis. However, in a clinical setting, patient 1 cells were generated from bone-marrow-derived cells in vitro and transfected with CcnE1-siRNA (CcnE1-si) or scrambled siRNA (scr-si). Proliferation analysis was performed by staining with Ki-67 (green) and CD11b (red). Knockdown efficiency of CcnE1 by siRNA was determined by qPCR. *P < 0.05; ***P < 0.001. Abbreviations: DAPI, 4 0 ,6-diamidino-2-phenylindole; HPF, high-power field.
therapies will only be initiated after manifestation of liver fibrosis. The most important result of our study is the fact that treatment with CcnE1-siRNA even prevents progression of liver fibrosis if applied after onset of chronic liver injury. We believe that this approach could be a promising treatment option for patients with liver fibrosis.
The underlying antifibrotic mechanism of CcnE1-siRNA turned out to be more complex than initially anticipated because it involved general hepatoprotective effects (i.e., reduced serum transaminase levels, attenuated inflammatory response, and accelerated tissue repair) after acute and chronic CCl 4 treatment. We determined the in vivo biodistribution of siRNA and Gene expression analysis of CcnE1 and CcnE2. *P < 0.05; **P < 0.01; ***P < 0.001. Abbreviation: n.s., not significant. identified the liver as the predominant target organ, excluding potential collateral effects of CcnE1-siRNA in other organs after systemic application. However, besides HSCs, we identified hepatocytes, CD11b 1 myeloid cells, and CD31
1 endothelial cells as relevant target cell populations of siRNA delivery in the liver. We excluded endothelial cells from further analysis because CcnE1-siRNA did not modulate their proliferation during fibrogenesis.
However, CCl 4 induced proliferation of CD11b 1 myeloid cells and other CD45 1 leukocytes under acute and chronic conditions, which was significantly diminished by CcnE1-siRNA. The requirement of CcnE1 for myeloid cell proliferation could be confirmed in vitro and thus seems to be a general biological mechanism, thereby excluding proliferation control through paracrine effects of the CcnE1-deficient cell environment.
We did not dissect the inflammatory milieu of CcnE1-depleted livers in more detail because this was beyond the scope of the present study and will be addressed in future work. Nevertheless, our data support the hypothesis that prevention of innate immune cell proliferation by CcnE1-siRNA contributes to its general hepatoprotective, anti-inflammatory, and antifibrotic effects. The reduced inflammatory response attributed to CcnE1-siRNA treatment was further supported by reduced MCP-1 expression and enhanced IL-10 induction in acute liver injury and chronic liver injury models. The role of proliferating macrophages during liver fibrogenesis is controversially discussed, (21, 22) and our data supports a function of CcnE1 for proliferation of leukocytes. Altogether, we conclude that CcnE1-siRNA therapy is capable of reducing the overall inflammatory response in the liver by inhibiting the proliferation of immune cell compartments.
In addition, we were surprised to observe accelerated tissue repair in CcnE1-siRNA-treated livers after induction of acute injury despite delayed hepatocyte proliferation. We excluded the possibility that CcnE1-siRNA treatment simply reduces the level of CCl 4 -mediated liver injury through unspecific hepatoprotective effects. In fact, the initial strength of liver damage was equivalent in scr-siRNA and CcnE1-siRNA treatment groups, when the wave of compensatory proliferation was not yet induced. Thus, the hepatoprotective and antifibrotic effects of CcnE1-siRNA seem to be dependent on its antiproliferative potential.
Our findings indicate that CcnE1 is more relevant for hepatocyte proliferation after toxic injury and less important following mechanical damage as observed in the PH model, which is, however, fully consistent with our previous studies. (9, 10) Our morphometric analyses suggest that tissue repair after CCl 4 /CcnE1-siRNA treatment occurs predominantly by excessive hypertrophy of remnant hepatocytes in a first phase (24-48 hours posttreatment) and by delayed compensatory proliferation in a second phase (72 hours posttreatment). In fact, we previously reported that concomitant deletion of CcnE1 and Cdk2 in hepatocytes prevents proliferation post-PH and triggers hypertrophy as an effective alternative mode of liver regeneration. (8) It can even be speculated that delayed compensatory hepatocyte proliferation following genotoxic liver injury (attributed to CCl 4 ) is explicitly beneficial and indirectly antifibrotic given that it enables more-efficient DNA repair. This could prevent cell death attributed to replication of damaged DNA by several mechanisms. (11, 23, 24) This idea is further supported by our genetic studies using hepatocyte-specific CcnE1
Dhepa knockout mice in the CCl 4 model. Importantly, genetic ablation of CcnE1 also delays hepatocyte proliferation after toxic injury similar to CcnE1-siRNA-treated cells; yet, these mice show a tendency toward attenuated liver fibrosis, but normal inflammatory response. We therefore exclude a paracrine effect of CcnE1-depleted hepatocytes on leukocyte proliferation or infiltration. However, our data support the idea that impaired hepatocyte proliferation attributed to lack of CcnE1 may slightly dampen HSC activation.
Our data implicate that delayed hepatocyte proliferation attributed to CcnE1 inhibition is not harmful, at least in the CCl 4 model, because the liver can still regenerate through hypertrophy. However, we cannot completely rule out that CcnE1 inhibition may provoke detrimental side effects under less-toxic conditions, such as alcohol exposition, which will be addressed in future studies.
Taken together, we propose that CcnE1-siRNA acts antifibrotic by three different mechanisms: Primarily, it prevents the proliferation and survival of activated HSCs during chronic fibrosis progression, thereby reducing the formation of ECM. Second, it reduces the proliferation and infiltration of profibrotic leukocytes in the challenged liver and thereby attenuates the overall inflammatory response after profibrotic stimulation. Finally, and presumably less relevant, CcnE1-siRNA prevents premature compensatory proliferation of genotoxic injured hepatocytes and triggers fast hypertrophic tissue repair. This could contribute to reduced hepatocyte death and less production of HSCand leukocyte-activating danger-associated molecular patterns (DAMPs).
To date, several siRNA therapeutics are being tested in clinical trials. (13) Pioneering work targeted the prototypical fibrosis mediator, collagen1a1, using systemic (25) or even cell-directed siRNA delivery, (26, 27) resulting in remarkable reduction of collagen disposition in several established fibrosis models. In addition, RNAi-mediated systemic inhibition of the proapoptotic factor, BH3 domain-only death agonist (Bid), was successful for prevention of nonalcoholic steatohepatitis-induced liver fibrosis in mice. (15) In summary, RNAi-based therapy could be a promising therapeutic strategy for treatment of liver fibrosis in the future, and our study identifies the cell-cycle mediator, CcnE1, as another suitable target for this approach.
